Effects of glucagon‐like peptide‐1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study-Reference-Cited by-同舟云学术

Effects of glucagon‐like peptide‐1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study

Published:2021-06-16 Issue:12 Volume:12 Page:2162-2171
ISSN:2040-1116
Container-title:Journal of Diabetes Investigation
language:en
Short-container-title:J of Diabetes Invest

Author:

Kuwata Hitoshi¹²,Yabe Daisuke¹³⁴^ORCID,Murotani Kenta⁵^ORCID,Fujiwara Yuuka¹,Haraguchi Takuya¹²³,Kubota Sodai¹³^ORCID,Kubota‐Okamoto Saki¹³,Usui Ryota¹²^ORCID,Ishitobi Minori²,Yamazaki Yuji¹²,Hamamoto Yoshiyuki¹²^ORCID,Kurose Takeshi¹⁶^ORCID,Seino Yusuke⁷^ORCID,Yamada Yuichiro¹²,Seino Yutaka¹²^ORCID

Affiliation:

1. Yutaka Seino Distinguished Center for Diabetes Research Kansai Electric Power Medical Research Institute Kobe Japan

2. Center for Diabetes, Endocrinology and Metabolism Kansai Electric Power Hospital Osaka Japan

3. Department of Diabetes, Endocrinology and Metabolism Gifu University Graduate School of Medicine Gifu Japan

4. Division of Molecular and Metabolic Medicine Kobe University Graduate School of Medicine Kobe Japan

5. Biostatistics Center Graduate School of Medicine, Kurume University Kurume Japan

6. Nakanoshima Clinic Osaka Japan

7. Department of Endocrinology and Metabolism Fujita Health University Toyoake Japan

Funder

Japan Association for Diabetes Education and Care

Japan Society for the Promotion of Science

Publisher

Wiley

Subject

General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdi.13598

Reference40 articles.

1. The journey to understanding incretin systems: Theory, practice and more theory

2. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art

3. Incretin therapy for diabetes mellitus type 2

4. Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease

5. GIP and GLP-1, the two incretin hormones: Similarities and differences

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Impact of GLP-1 Receptor Agonists on Endoscopic Patient Outcomes in an Ambulatory Setting: A Retrospective Study at a Large Tertiary Center;Journal of Clinical Medicine;2024-09-12

2. Confounding Factors in the Association Between Glucagon-Like Peptide-1 Receptor Agonist Use and Retained Gastric Contents in Asymptomatic Patients Undergoing Upper Gastrointestinal Endoscopy: A Retrospective Study;Cureus;2024-09-11

3. Diabetes and Osteoarthritis: Exploring the Interactions and Therapeutic Implications of Insulin, Metformin, and GLP-1-Based Interventions;Biomedicines;2024-07-23

4. Reflections on the discovery GLP-1 as a satiety hormone: Implications for obesity therapy and future directions;European Journal of Clinical Nutrition;2024-06-18

5. Glucagon-Like Peptide-1 Receptor Agonist Use and Residual Gastric Content Before Anesthesia;JAMA Surgery;2024-06-01